还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

7 F$ z& _: {& a0 S                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

0 r2 R' q# ~. Q3 d# i' c可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  


Sub-category:
8 B  M$ I; {* `; ^3 j  hMolecular Targets


Category:
Tumor Biology


1 T4 V. R- \8 n- E/ c$ \" VMeeting:
/ M: ^& Z& z+ D* s! T. E2011 ASCO Annual Meeting
" H% E9 x; {% e# s% M0 s3 a* W6 r

& \8 S! ^7 W3 k% ESession Type and Session Title:
3 r- g# y& ]) @/ R% H" X: [9 BPoster Discussion Session, Tumor Biology

: M# W4 Z8 `% ]" O8 g/ X% P# j0 R
- I  b" Y  O; ], MAbstract No:
& J5 s- x( R( B10517


0 [! a" D* u2 A# LCitation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)
1 [, Y. ^4 D2 q2 x9 a5 o0 B! V/ v
6 `% Z2 w' O, Q( W( s: F. D
" m8 H2 l2 `9 Y* X. c- N0 Y& j7 wAuthor(s):
. j) M; E( A% C, ]7 D4 \J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
" w) N& {' b8 Q8 P
0 E0 _  f" n1 Z$ r  h( E

9 X6 @1 }8 h+ ^, p  C9 R( cAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
4 i4 F8 s3 J' h7 \
Abstract Disclosures

3 M1 e' e1 n3 n6 h- [. }3 f. ~Abstract:


7 ]9 v/ W. G% G- z) WBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

1 a5 ^/ I5 ^1 M4 h7 l- g  H
* y( }4 F2 I* E6 I& d( d* w

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

- ?1 ?+ c, {  d, v+ ?7 t                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

, U) I2 b( i4 n# R易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
2 I1 N1 D8 W6 D' `8 m/ p; t
8 t/ J, }- W- M9 j/ j现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊